PMID- 36106548
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20230118
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 9
IP  - 6
DP  - 2022 Dec
TI  - Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced 
      ejection fraction: The ARIADNE registry.
PG  - 4209-4218
LID - 10.1002/ehf2.14014 [doi]
AB  - AIMS: ARIADNE aimed to assess the association between effects of 
      sacubitril/valsartan and no sacubitril/valsartan treatment and clinical 
      characteristics, functional capacity, and clinical outcomes (cause-specific 
      mortality and hospitalizations) in outpatients with heart failure (HF) with 
      reduced ejection fraction (HFrEF). METHODS: ARIADNE was a prospective European 
      registry of 9069 patients with HFrEF treated by office-based cardiologists or 
      selected primary care physicians. Of the 8787 eligible for analysis, 4173 
      patients were on conventional HF treatment (non-S/V group), whereas 4614 patients 
      were either on sacubitril/valsartan treatment at enrolment or started 
      sacubitril/valsartan within 1 month of enrolment (S/V group). We also generated a 
      restricted analysis set (rS/V) including only those 2108 patients who started 
      sacubitril/valsartan treatment within the month prior to or after enrolment. 
      RESULTS: At the baseline, average age of patients enrolled in the study was 
      68 years, and 23.9% (2099/8787) were female. At the baseline, the proportions of 
      patients with New York Heart Association (NYHA) Class III symptoms were 30.9 
      (1288/4173), 42.8 (1974/4614), and 48.2% (1015/2108), in non-S/V, S/V, and rS/V 
      groups, respectively. After 12 months of treatment, the proportion of patients 
      with NYHA Class III at baseline who improved to Class II was 32.0% (290/907) in 
      the non-S/V group vs. 46.3% (648/1399) in S/V group and 48.7% (349/717) in rS/V 
      group. The overall mortality rate was 5.0 per 100 patient-years. Rates of HF 
      hospitalizations were high (20.9, 20.3, and 21.2 per 100 patient-years in the 
      non-S/V, S/V, and rS/V groups, respectively). Emergency room visits without 
      hospitalization occurred in 3.9, 3.2, and 3.9% of patients in the non-S/V, S/V, 
      and rS/V groups, respectively. CONCLUSIONS: This large HFrEF European registry 
      provides a contemporary outcome profile of outpatients with HFrEF treated with or 
      without sacubitril/valsartan. In a real-world setting, sacubitril/valsartan was 
      associated with an improvement of symptoms in patients with HFrEF compared with 
      the conventional HFrEF treatment.
CI  - (c) 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of European Society of Cardiology.
FAU - Maggioni, Aldo P
AU  - Maggioni AP
AUID- ORCID: 0000-0003-2764-6779
AD  - Heart Care Foundation ANMCO Research Centre, Florence, Italy.
FAU - Clark, Andrew L
AU  - Clark AL
AD  - Hull University Teaching Hospitals NHS Trust, Hull, UK.
FAU - Barrios, Vivencio
AU  - Barrios V
AD  - University Hospital Ramon y Cajal, Madrid, Spain.
FAU - Damy, Thibaud
AU  - Damy T
AD  - University Hospital Henri Mondor, Creteil, France.
FAU - Drozdz, Jaroslaw
AU  - Drozdz J
AD  - Medical University of Lodz, Lodz, Poland.
FAU - Fonseca, Candida
AU  - Fonseca C
AD  - Hospital de Sao Francisco Xavier, Lisbon, NOVA Medical School, Faculdade de 
      Ciencias Medicas, Universidade Nova de Lisboa, Lisbon, Portugal.
FAU - Lund, Lars H
AU  - Lund LH
AD  - Department of Medicine, Karolinska Institutet and Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - Kalus, Stefanie
AU  - Kalus S
AD  - GKM Gesellschaft fur Therapieforschung mbH, Munich, Germany.
FAU - Ferber, Philippe C
AU  - Ferber PC
AD  - Novartis Pharma, Basel, Switzerland.
FAU - Hussain, Rizwan I
AU  - Hussain RI
AD  - Arxx Therapeutics, Oslo, Norway.
FAU - Koch, Cornelia
AU  - Koch C
AD  - Novartis Pharma, Basel, Switzerland.
FAU - Zeymer, Uwe
AU  - Zeymer U
AD  - Klinikum Ludwigshafen and Institut fur Herzinfarktforschung, 
      Ludwigshafen-am-Rhein, Germany.
CN  - ARIADNE investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220915
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
RN  - 0 (Tetrazoles)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 80M03YXJ7I (Valsartan)
RN  - 0 (Aminobutyrates)
RN  - 0 (Biphenyl Compounds)
SB  - IM
MH  - Humans
MH  - Female
MH  - Aged
MH  - Male
MH  - *Heart Failure
MH  - Outpatients
MH  - Prospective Studies
MH  - Tetrazoles/therapeutic use
MH  - Stroke Volume
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Valsartan/therapeutic use
MH  - Aminobutyrates/therapeutic use
MH  - Biphenyl Compounds/therapeutic use
MH  - Registries
PMC - PMC9773755
OTO - NOTNLM
OT  - ARNI
OT  - Heart failure
OT  - Heart failure with reduced ejection fraction
OT  - Outcomes
OT  - Outpatients
OT  - Sacubitril/valsartan
COIS- APM reports personal fees from Novartis during the conduct of the study and 
      personal fees from Bayer, personal fees from AstraZeneca, and personal fees from 
      Fresenius, outside the submitted work. ALC reports personal fees and 
      non-financial support from Novartis during the conduct of the study. VB declares 
      grants and personal fees from Novartis during the conduct of the study and 
      personal fees from Astra Zeneca and Boehringer Ingelheim-Lilly Alliance. TD 
      reports grants and personal fees from Pfizer, grants and personal fees from 
      Novartis, grants and personal fees from Bayer, and personal fees from Astra 
      Zeneca, outside the submitted work. JD has nothing to disclose. CF reports 
      personal fees from Novartis during the conduct of the study personal fees from 
      Servier, personal fees and other from AstraZeneca, personal fees and other from 
      Bayer, personal fees and other from Vifor Pharma, personal fees and other from 
      Novartis, and other from Boehringer, outside the submitted work. LHL reports 
      grants and personal fees from Novartis, during the conduct of the study; personal 
      fees from Merck, personal fees from Sanofi, grants and personal fees from 
      Vifor-Fresenius, grants and personal fees from AstraZeneca, grants and personal 
      fees from Relypsa, personal fees from Bayer, grants from Boston Scientific, 
      personal fees from Pharmacosmos, personal fees from Abbott, grants and personal 
      fees from Mundipharma, personal fees from Medscape, personal fees from Myokardia, 
      and grants and personal fees from Boehringer Ingelheim, outside the submitted 
      work. SK is an employee of GKM (clinical research organization) contracted for 
      data analysis by Novartis and received fees from Novartis during the conduct of 
      the study. PCF and CK are employees of Novartis. RIH was an employee of Novartis 
      when the study was conducted. UZ reports grants and personal fees from Novartis 
      during the conduct of the study and grants and personal fees from Astra Zeneca, 
      personal fees from Boehringer Ingelheim, grants and personal fees from BMS, 
      personal fees from MSD, personal fees from Sanofi, grants and personal fees from 
      Pfizer, personal fees from Trommsdorf, personal fees from Amgen, and grants and 
      personal fees from Bayer, outside the submitted work.
EDAT- 2022/09/16 06:00
MHDA- 2022/12/24 06:00
PMCR- 2022/09/15
CRDT- 2022/09/15 05:03
PHST- 2022/04/19 00:00 [revised]
PHST- 2022/01/11 00:00 [received]
PHST- 2022/06/03 00:00 [accepted]
PHST- 2022/09/16 06:00 [pubmed]
PHST- 2022/12/24 06:00 [medline]
PHST- 2022/09/15 05:03 [entrez]
PHST- 2022/09/15 00:00 [pmc-release]
AID - EHF214014 [pii]
AID - 10.1002/ehf2.14014 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2022 Dec;9(6):4209-4218. doi: 10.1002/ehf2.14014. Epub 2022 Sep 
      15.